1 Sztriha LK， Sas K， Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci. 2005; （229-230）: 163-169. 2 Weber ZZ， Zimmermann KC， Meyer-Kirchrath J， et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999; 353: 900.3 Weber AA， Przytulski B， Schumacher M， et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients under-going coronary artery bypass grafting. Br J Haematol. 2002; 117（2）: 424-426.4 Rocca B， Secchiero P， Ciabattoni G， et al. Cyclooxyge-nase-2 expression is induced during human megakaryo-poiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002; 99: 7634-7639.5 Kimmel SE， Berlin JA， Reilly M， et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142（3）: 157-164. 6 Johnsen SP， Larsson H， Tarone RE， et al. Risk of hospitalization for myocardial infarction among users of rofecoxib， celecoxib， and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005; 165（9）: 978-984. 7 Nurtjahja-Tjendraputra E， Ammit AJ， Roufogalis BD， et al. Effective anti-platelet and COX-1 enzyme inhibi-tors from pungent constituents of ginger. Thromb Res. 2003; 111（4-5）: 259-265. 8 Catella-Lawson F， Reilly MP， Kapoor SC， et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345（25）: 1809-1817. 9 Cryer B， Berlin RG， Cooper SA， et al. Double-blind， randomized， parallel， placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther. 2005; 27（2）: 185-191.10 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs. 2004; 4（3）: 151-158.帮我翻译成中文
